drugset / Trial / NCT00839852

A Study of Cariprazine in Patients With Chronic Stable Schizophrenia

NCT00839852

Phase 2 Completed 97 enrolled Forest Laboratories Gedeon Richter Ltd. · collab
NaSingle-groupOpen-labelTreatment

Summary

This is an outpatient study to evaluate the long-term safety, tolerability, and pharmacokinetics of cariprazine in patients with schizophrenia.

Timeline

Start
2009-05-31
Primary completion
2010-08-31
Completion
2010-08-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Cariprazine Small molecule 1.5 mg

Indications